Synaptogenix signs memorandum of understanding with nemours a.i. dupont hospital to initiate trial using bryostatin, under orphan drug status, to treat fragile x syndrome

New york, aug. 5, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding ("mou") with the nemours a.i. dupont hospital for children, an internationally recognized leader in the comprehensive care of childhood diseases, with the intention of initiating a trial to treat fragile x with bryostatin.
SNPX Ratings Summary
SNPX Quant Ranking